Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | GBA1 | P04062 | 12/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28267000 | 0.79 | SMPD1 (0.52) | SMPD1GBA1EPHX2 | |
| SCHEMBL626456 | 0.75 | SMPD1 (0.44) | SMPD1GBA1EPHX2 | |
| SCHEMBL1165614 | 0.74 | GBA1 (0.50) | SMPD1GBA1EPHX2 | |
| SCHEMBL16526395 | 0.72 | SMPD1 (0.51) | SMPD1GBA1 | |
| SCHEMBL24674920 | 0.71 | EPHX2 (0.55) | SMPD1GBA1EPHX2 | |
| SCHEMBL544804 | 0.70 | SMPD1 (0.54) | SMPD1GBA1 | |
| SCHEMBL5021078 | 0.70 | GBA1 (0.56) | SMPD1GBA1EPHX2 | |
| SCHEMBL16263567 | 0.70 | SMPD1 (0.54) | SMPD1GBA1 | |
| SCHEMBL14289745 | 0.70 | SMPD1 (0.54) | SMPD1GBA1 | |
| SCHEMBL22054908 | 0.70 | EPHX2 (0.57) | GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1720860-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080379-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | SMPD1 4188/4885GBA1 2211/4885EPHX2 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.